| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/IJO.2017.138 |
| P698 | PubMed publication ID | 28588304 |
| P50 | author | Ana B. Crujeiras | Q47188102 |
| Daniel Antonio de Luis | Q51351179 | ||
| Diego Gomez-Arbelaez | Q56572666 | ||
| Manuel Macias-Gonzalez | Q59670616 | ||
| Ignacio Sajoux | Q61314638 | ||
| Diego Bellido | Q42820413 | ||
| P2093 | author name string | F F Casanueva | |
| M C Carreira | |||
| J A Martinez | |||
| A Sueiro | |||
| J Baltar | |||
| F J Tinahones | |||
| M A Zulet | |||
| I Baamonde | |||
| A I Castro | |||
| P2860 | cites work | Identification of a novel FGF, FGF-21, preferentially expressed in the liver | Q22254289 |
| Different roles of N- and C- termini in the functional activity of FGF21 | Q24312210 | ||
| FGF21 N- and C-termini play different roles in receptor interaction and activation | Q24322074 | ||
| Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Q46770146 | ||
| Scientific Opinion on the essential composition of total diet replacements for weight control | Q47156617 | ||
| Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents | Q47261474 | ||
| A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management | Q47377383 | ||
| Clinical impact of Mediterranean-enriched-protein diet on liver size, visceral fat, fat mass, and fat-free mass in patients undergoing sleeve gastrectomy. | Q47382469 | ||
| Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels | Q47418791 | ||
| Severe protein-calorie malnutrition after bariatric procedures | Q47958352 | ||
| Pharmacological management of obesity: an endocrine Society clinical practice guideline | Q48134469 | ||
| Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework. | Q51278414 | ||
| Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease. | Q51511659 | ||
| Photoperiodic regulation of FGF21 production in the Siberian hamster. | Q51748272 | ||
| Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial. | Q53765902 | ||
| Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects | Q57148414 | ||
| Interplay of atherogenic factors, protein intake and betatrophin levels in obese–metabolic syndrome patients treated with hypocaloric diets | Q59800584 | ||
| Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity | Q59800840 | ||
| Differential Expression of Oxidative Stress and Inflammation Related Genes in Peripheral Blood Mononuclear Cells in Response to a Low-Calorie Diet: A Nutrigenomics Study | Q59803372 | ||
| Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients | Q60636813 | ||
| Multivitamin prophylaxis in prevention of post-gastric bypass vitamin and mineral deficiencies | Q67782655 | ||
| Obese patients have inadequate protein intake related to protein intolerance up to 1 year following Roux-en-Y gastric bypass | Q73110315 | ||
| Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers | Q83400241 | ||
| Rapid increase in fibroblast growth factor 21 in protein malnutrition and its impact on growth and lipid metabolism - ERRATUM | Q86244790 | ||
| Incidence and Clinical Features of Diabetic Ketoacidosis After Bariatric and Metabolic Surgery | Q87178797 | ||
| Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway | Q24607012 | ||
| Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 | ||
| Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants | Q26749640 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Human FGF-21 Is a Substrate of Fibroblast Activation Protein | Q28550659 | ||
| FGF21 is an endocrine signal of protein restriction | Q28572009 | ||
| A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis | Q28588558 | ||
| Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis | Q34019712 | ||
| A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain | Q34305197 | ||
| Management of obesity | Q34513665 | ||
| Mechanisms, Pathophysiology, and Management of Obesity | Q34549588 | ||
| Fibroblast growth factor 21 is a metabolic regulator that plays a role in the adaptation to ketosis. | Q34674492 | ||
| The role of higher protein diets in weight control and obesity-related comorbidities | Q35583257 | ||
| FGF21 and the late adaptive response to starvation in humans | Q36335835 | ||
| Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial | Q36646856 | ||
| Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21 | Q36674741 | ||
| Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease | Q36889026 | ||
| Brown adipose tissue and novel therapeutic approaches to treat metabolic disorders. | Q38272618 | ||
| FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss | Q38392464 | ||
| Fibroblast growth factor-21, energy balance and obesity | Q38594676 | ||
| FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties | Q38613510 | ||
| Crosstalk between adipokines and myokines in fat browning | Q38797210 | ||
| Overview on nutritional issues in bariatric surgery | Q38811218 | ||
| Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes | Q38829862 | ||
| Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects. | Q38835938 | ||
| Obesity as a disease: has the AMA resolution had an impact on how physicians view obesity? | Q38905157 | ||
| FGF21 reloaded: challenges of a rapidly growing field | Q39798117 | ||
| Red meat intolerance in patients submitted to gastric bypass: a 4-year follow-up study | Q41103245 | ||
| Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients | Q42863093 | ||
| Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. | Q43287114 | ||
| Body Composition Changes After Very-Low-Calorie Ketogenic Diet in Obesity Evaluated by 3 Standardized Methods | Q43355523 | ||
| Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. | Q44537919 | ||
| Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. | Q45066118 | ||
| Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction | Q45335817 | ||
| A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project. | Q45899553 | ||
| The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. | Q46445480 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| P304 | page(s) | 1570-1578 | |
| P577 | publication date | 2017-06-07 | |
| P1433 | published in | International Journal of Obesity | Q6051519 |
| P1476 | title | Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress? | |
| P478 | volume | 41 |
| Q42362307 | Acid-base safety during the course of a very low-calorie-ketogenic diet |
| Q64115334 | Activation of hepatic estrogen receptor-α increases energy expenditure by stimulating the production of fibroblast growth factor 21 in female mice |
| Q90221587 | Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease |
| Q90634018 | Circulating Diabetic Candidate Neurotrophic Factors, Brain-Derived Neurotrophic Factor and Fibroblast Growth Factor 21, in Sleeve Gastrectomy |
| Q58702386 | Effect of A Very Low-Calorie Ketogenic Diet on Food and Alcohol Cravings, Physical and Sexual Activity, Sleep Disturbances, and Quality of Life in Obese Patients |
| Q90567494 | Effect of a Very-Low-Calorie Ketogenic Diet on Circulating Myokine Levels Compared with the Effect of Bariatric Surgery or a Low-Calorie Diet in Patients with Obesity |
| Q90224598 | Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges |
| Q93251897 | Serum asprosin levels and bariatric surgery outcomes in obese adults |
| Q96432127 | Weight loss normalizes enhanced expression of the oncogene survivin in visceral adipose tissue and blood leukocytes from individuals with obesity |
Search more.